What is on the differential diagnosis for Endometrial Cancer?

Key differentials include Endometrial polyp, Endometrial hyperplasia (without/with atypia), Submucosal fibroid, Atrophic endometrium / vaginitis, Cervical cancer, Anticoagulant-associated bleeding, Hormone therapy-related bleeding.

What are the high-yield PANCE pearls for Endometrial Cancer?

Any postmenopausal bleeding requires endometrial evaluation regardless of TVUS findings if bleeding persists or recurs. Endometrial stripe >4 mm in postmenopausal woman with bleeding mandates endometrial sampling. Universal MMR/MSI screening on all endometrial cancers identifies Lynch syndrome and guides immunotherapy eligibility. Atypical endometrial hyperplasia (EIN) coexists with endometrial cancer in 30-40% of cases — hysterectomy is the standard. Tamoxifen increases endometrial cancer risk ~2-3x; any abnormal bleeding warrants prompt evaluation. Progestin therapy can reverse endometrial hyperplasia and (less reliably) early grade 1 endometrioid cancer in fertility-sparing settings.

Reproductive · PANCE / PANRE

Endometrial Cancer

Written & clinically reviewed by Ryan Busch, PA-C · Updated July 2026 · Report an error

Most common gynecologic malignancy in the US — postmenopausal bleeding is the cardinal red flag.

Also known as: endometrial cancer, uterine cancer, endometrial adenocarcinoma, endometrial hyperplasia

Overview

Malignancy arising from the endometrial lining of the uterus, most commonly endometrioid adenocarcinoma. Bokhman's traditional dual classification distinguishes Type I (estrogen-dependent endometrioid, ~80%, usually low-grade, favorable prognosis) from Type II (non-estrogen-dependent serous, clear cell, carcinosarcoma, higher grade, worse prognosis). The Cancer Genome Atlas (TCGA) molecular subtypes (POLE ultramutated, MSI-high, copy-number low, copy-number high) increasingly guide prognosis and therapy.

Epidemiology

Most common gynecologic malignancy in developed countries; ~66,000 new US cases/year, ~12,000 deaths. Median age at diagnosis ~62. Incidence rising with obesity epidemic.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Endometrial Cancer outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Unopposed estrogen exposure: obesity (peripheral conversion), nulliparity, early menarche, late menopause, anovulatory cycles (PCOS), estrogen-only HRT, granulosa cell tumor
Tamoxifen use
Diabetes mellitus, hypertension, metabolic syndrome
Lynch syndrome (HNPCC) — 40-60% lifetime risk; consider age <50 at diagnosis
Cowden syndrome (PTEN)
Older age

Pathophysiology

Type I cancers arise from chronic unopposed estrogen stimulation producing endometrial hyperplasia → atypical hyperplasia (endometrial intraepithelial neoplasia, EIN) → endometrioid adenocarcinoma; mutations in PTEN, KRAS, mismatch repair genes. Type II cancers arise from atrophic endometrium independent of estrogen, with TP53 mutations and aneuploidy.

Clinical presentation

Symptoms

Postmenopausal bleeding (cardinal symptom — present in ~90%)
Heavy or irregular bleeding in perimenopause
Intermenstrual bleeding in premenopausal women
Pelvic pain, weight loss (advanced)
Abnormal vaginal discharge

Signs / physical exam

Often normal pelvic exam in early disease
Enlarged or tender uterus
Adnexal mass (synchronous ovarian primary or metastasis)
Obesity is the most common physical finding

Classic findings

Postmenopausal obese, diabetic woman with new vaginal bleeding; endometrial stripe >4 mm on TVUS.

Differential diagnosis

Endometrial polyp — Bleeding without dysplasia; saline sonohysterography or hysteroscopy
Endometrial hyperplasia (without/with atypia) — Premalignant; managed with progestin or hysterectomy
Submucosal fibroid — Heavy or intermenstrual bleeding; TVUS
Atrophic endometrium / vaginitis — Common cause of postmenopausal bleeding; pale thin mucosa
Cervical cancer — Postcoital bleeding, visible lesion
Anticoagulant-associated bleeding — Workup still required — coagulopathy does not explain new bleeding without evaluation
Hormone therapy-related bleeding — Common during first 6 months of continuous HT; evaluate if persistent

Diagnostic workup

Diagnostic criteria

Tissue diagnosis required. FIGO 2009 (with 2023 revision) surgical staging: I (confined to uterus), II (cervical stromal invasion), III (local/regional spread), IV (distant or bladder/bowel invasion).

Labs

CBC, BMP
Pregnancy test if reproductive age
CA-125 in select high-risk or advanced cases (not screening)

Imaging

Transvaginal ultrasound — endometrial thickness >4 mm in postmenopausal woman warrants biopsy; <4 mm has high NPV but biopsy still indicated if persistent bleeding
Endometrial biopsy (Pipelle) — first-line tissue diagnosis; office procedure
Hysteroscopy with directed biopsy or dilation and curettage — if Pipelle nondiagnostic or insufficient
MRI pelvis — preoperative staging (myometrial invasion depth)
CT chest/abdomen/pelvis — staging in high-grade or advanced disease
Lynch syndrome screening (universal MMR/MSI testing on all endometrial cancers) per NCCN/SGO

Diagnostic algorithm

flowchart TD
  A[Postmenopausal bleeding<br/>OR AUB with risk factors] --> B[TVUS]
  B --> C{Endometrial<br/>thickness?}
  C -->|>4 mm or persistent bleed| D[Endometrial biopsy]
  C -->|≤4 mm, single episode| E[Observation;<br/>biopsy if recurrent]
  D --> F{Pathology}
  F -->|Hyperplasia<br/>without atypia| G[Progestin × 3-6 mo<br/>Re-biopsy]
  F -->|Atypical hyperplasia<br/>EIN| H[Hysterectomy preferred<br/>30-40% concurrent cancer]
  F -->|Endometrial cancer| I[MRI pelvis + staging<br/>MMR/MSI testing]
  I --> J{Stage}
  J -->|I-II| K[TH + BSO ± LND<br/>± adjuvant therapy]
  J -->|III-IV| L[Cytoreduction +<br/>chemo ± radiation]
  J -->|Recurrent| M[Chemo, immunotherapy,<br/>hormone therapy]

Evaluation of postmenopausal bleeding through endometrial cancer treatment.

Treatment

First-line

Stage I-II: total hysterectomy + bilateral salpingo-oophorectomy ± pelvic/para-aortic lymphadenectomy (or sentinel lymph node mapping)
Adjuvant therapy by risk: observation (low risk), vaginal brachytherapy (intermediate), external-beam radiation ± chemotherapy (high-intermediate or high)
Stage III-IV: maximal cytoreductive surgery + adjuvant chemotherapy (carboplatin + paclitaxel) ± radiation
Recurrent/metastatic: chemotherapy; immunotherapy (pembrolizumab + lenvatinib for MMR-proficient; pembrolizumab or dostarlimab for MMR-deficient); hormone therapy for low-grade endometrioid

Endometrial hyperplasia

Without atypia: progestin therapy (medroxyprogesterone, megestrol, levonorgestrel IUD) for 3-6 months; repeat biopsy
With atypia (EIN): hysterectomy is preferred — 30-40% risk of concurrent endometrial cancer; fertility-sparing levonorgestrel IUD or high-dose progestin with close surveillance if highly motivated patient

Fertility-sparing for early endometrioid

Grade 1 endometrioid limited to endometrium (no myometrial invasion on MRI), no extrauterine disease, strong fertility desire
Levonorgestrel IUD ± megestrol; repeat biopsy q3-6 months
Definitive hysterectomy after childbearing complete

Lynch syndrome surveillance

Annual endometrial biopsy starting age 30-35
Consider risk-reducing hysterectomy + BSO after childbearing complete
Colonoscopy screening per Lynch protocols

Complications

Postoperative complications (DVT/PE, infection, bowel injury)
Lymphedema after lymphadenectomy
Pelvic radiation toxicity (cystitis, proctitis, vaginal stenosis)
Recurrence — most within 2-3 years
Concurrent ovarian primary or metastasis in ~5% of premenopausal cases

PANCE pearls

Any postmenopausal bleeding requires endometrial evaluation regardless of TVUS findings if bleeding persists or recurs.
Endometrial stripe >4 mm in postmenopausal woman with bleeding mandates endometrial sampling.
Universal MMR/MSI screening on all endometrial cancers identifies Lynch syndrome and guides immunotherapy eligibility.
Atypical endometrial hyperplasia (EIN) coexists with endometrial cancer in 30-40% of cases — hysterectomy is the standard.
Tamoxifen increases endometrial cancer risk ~2-3x; any abnormal bleeding warrants prompt evaluation.
Progestin therapy can reverse endometrial hyperplasia and (less reliably) early grade 1 endometrioid cancer in fertility-sparing settings.

References

NCCN Uterine 2024 — NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms
ACOG PB 149 — ACOG Practice Bulletin No. 149: Endometrial Cancer
ACOG CO 631 — ACOG Committee Opinion 631: Endometrial Intraepithelial Neoplasia
FIGO 2023 — FIGO Staging of Endometrial Cancer 2023 (Berek et al., Int J Gynaecol Obstet 2023)

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.